TRV stock is in a base with a buy point of 269.56. The blue dot on IBD MarketSurge shows that its relative strength line is at a new high. Health Care Stocks. A few biotechs are a ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of ...

Considering taking supplements to treat inflammatory bowel disease ibd? Below is a list of common ... dosage details and user reviews for the vitamins and supplements listed below.

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...

The topic of biologic therapy for IBD has been selected for this Focus issue of Nature Reviews Gastroenterology & Hepatology because of the important implications it has for disease management.